Amillo-5MER (TFA)

Amilo-5MER (5-MP) TFA is an orally active and selective Serum Amyloid A (SAA) inhibitor. Amilo-5MER TFA specifically inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β from SAA-activated cells. Amilo-5MER TFA reduces chronic inflammation and relieves symptoms of diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and multiple sclerosis (MS) . Amilo-5MER TFA is promising for research of autoimmune diseases and chronic inflammatory diseases[1].

5-MP (TFA)

12352209

Amyloid-β; Interleukin Related

Immunology/Inflammation; Neuronal Signaling

Neuroscience-Neurodegeneration

Inflammation/Immunology

99.63

0.1 M Acetic acid : 0.5 mg/mL (ultrasonic) |DMSO : 25 mg/mL (ultrasonic)

CC(C)[C@@H](C(N)=O)NC([C@H](CC(O)=O)NC([C@H](C)NC([C@H]([C@H](O)C)NC([C@@H](NC(C)=O)CCSC)=O)=O)=O)=O.O=C(C(F)(F)F)O.[x]

C23H40N6O9S.xC2HF3O2

576.66 (free base)

[1]Hemed-Shaked M, et al. MTADV 5-MER peptide suppresses chronic inflammations as well as autoimmune pathologies and unveils a new potential target-Serum Amyloid A. J Autoimmun. 2021 Nov;124:102713.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10935A/Amilo-5MER-TFA-SDS-MedChemExpress.pdf

Peptides

Phase 1